cardiodiagnosticsinc.com (CDIO): יחס מחיר להכנסות חזויות

Cardio Diagnostics is implementing precision EpiCheck AI algorithms for autonomous epigenetic DNA analysis. This chart in the GURU.Markets terminal displays the forward P/S indicator, which has captured the metric at 278.00. The company's US-based retail business model minimizes geopolitical risks, although Cardio Diagnostics faces a fierce battle for insurance provider recognition within the growing digital diagnostics sector.

Forward P/S relates current market capitalization to expected revenue, allowing for a business valuation relative to future cash flows while filtering out market noise. For Cardio Diagnostics (CDIO), this indicator reflects the scaling pace of genetic test sales within preventive medicine clinics, while the forward P/S trend helps determine whether the market price is fair relative to the actual growth in demand for cardiac diagnostics.